Sun, Dec 28, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Jeffrey Strauss returns to Butterfield Fulcrum to head US Operations

Wednesday, July 13, 2011
Opalesque Industry Update - Senior industry executive Jeffrey Strauss has returned to Butterfield Fulcrum, a top five independent fund services provider, to head US operations. As President of Butterfield Fulcrum Group (US) Inc, Mr. Strauss will be responsible for all aspects of the US market for the company including sales, marketing, operations and growth.

“Jeff is a senior and seasoned industry executive and we are delighted to welcome him back to Butterfield Fulcrum, where he will be responsible for further strengthening our client relationships and our industry presence, “ said Glenn Henderson, CEO of Butterfield Fulcrum. “With Jeff’s return our focus will be to strengthen our middle office offering as part of our whole services solution. Jeff brings extensive experience with full service client solutions both for fund administration and the alternative asset management sector that will be of immediate benefit to our clients.”

“Butterfield Fulcrum is poised to build on its reputation as a leading independent fund administrator and I am extremely pleased to be re-joining the team to help lead that effort,” said Mr. Strauss, who will report directly to Mr. Henderson. “This senior management team has many years of joint experience and under Glenn’s leadership we are again directing all of our efforts to providing our clients with an unrivalled full service fund administration service model.”

Mr. Strauss brings more than 30 years experience in financial services and the alternative asset management sector with a focus on client services, fund administration, prime brokerage, hedge funds and broker dealers. Most recently, he was Global Head of Sales of HedgeServ Corp. and before that was Managing Director of Business Development at Butterfield Fulcrum. Prior, he was a consultant to Sierra Global, a European long short hedge fund. Mr. Strauss retired from Goldman Sachs in March 2006 after 23 years at the investment banking firm. At the time of his retirement he was the Chief of Staff for the US Client Services Group. Before being named Chief of Staff, he managed the Prime Brokerage Sales and Marketing team focused on fundamental long/short hedge funds.

(press release)

Source

kb

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its